Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
BHP Faces AU$1.3 Billion Wage Adjustment for Queensland...
​Royal Gold to Create Streaming and Royalty Giant...
Chris Berry: The West Must Invest in Refinement...
Torex Gold Moves Beyond Single-Asset Status With Reyna...
Ekin Ober on Why AI Could Be Mining’s...
Maritime Resources: A Low-risk Path to Gold Production...
Stallion Uranium Provides Update on Technology Data Acquisition...
Trump Tariffs to Raise US Medical Device Costs,...
EVs Now Emit 73 percent Less Than Gasoline...
OpenAI to release web browser in challenge to...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by admin September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Saskatchewan Research Council Achieves Commercial Production at Rare Earths Facility
next post
Lithium Universe Limited (ASX: LU7) – Trading Halt

You may also like

Allied Critical Metals

June 20, 2025

After US$1.5 Billion Gold Payday, Chinese Billionaire Pivots...

May 22, 2025

Fund Manager: Gold Stocks a Strategic Opportunity for...

May 21, 2025

Brunswick Exploration Completes Brokered Private Placement for Gross...

May 31, 2025

Canadian Investment Regulatory Organization Trade Resumption – FYL

April 18, 2025

Oil Price and Inflation: What’s the Correlation?

May 15, 2025

Bold Ventures Signs Amendment to the Burchell Gold...

November 27, 2024

Adrian Day: Gold Stock Valuations at 40 Year...

March 8, 2025

LaFleur Minerals Provides Update on Beacon Mill Restart,...

March 22, 2025

Chris Vermeulen: Next Gold Targets and “Sweet Spot”...

December 17, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • BHP Faces AU$1.3 Billion Wage Adjustment for Queensland Coal Miners

      July 11, 2025
    • ​Royal Gold to Create Streaming and Royalty Giant in US$3.7 Billion Deal

      July 11, 2025
    • Chris Berry: The West Must Invest in Refinement Now or Fall Further Behind

      July 11, 2025
    • Torex Gold Moves Beyond Single-Asset Status With Reyna Silver Takeover

      July 11, 2025
    • Ekin Ober on Why AI Could Be Mining’s Most Valuable Tool Yet

      July 11, 2025
    Promotion Image

    banner ads

    Categories

    • Business (764)
    • Economy (829)
    • Investing (2,387)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved